Ruthenium polypyridyl complexes as PARP inhibitor sensitisers

This project aims to improve outcomes for patients in Wales with ovarian cancer by developing ruthenium-based compounds that enhance the effectiveness of PARP inhibitors (PARPi). While PARPi are currently effective in a subset of patients with BRCA mutations, many Welsh patients with BRCA-proficient tumours do not benefit. Creating compounds that “sensitize” these tumours to PARPi could directly increase access to precision therapies for Welsh patients, improving survival and tackling treatment inequalities locally.

This project develops ruthenium(II) polypyridyl compounds to create “chemical BRCAness,” enabling PARPi activity in BRCA-proficient tumours. Focusing on Welsh patients ensures preclinical optimisation and translational feasibility within NHS Wales. This approach addresses drug resistance expands access to targeted therapies, and aligns with Cancer Research Wales priority of mechanism-driven, precision oncology research across Wales.